|
US7411075B1
(en)
|
2000-11-16 |
2008-08-12 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form of atorvastatin calcium
|
|
US7501450B2
(en)
|
2000-11-30 |
2009-03-10 |
Teva Pharaceutical Industries Ltd. |
Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
|
IL156055A0
(en)
|
2000-11-30 |
2003-12-23 |
Teva Pharma |
Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
|
|
SK16002003A3
(sk)
|
2001-06-29 |
2004-12-01 |
Warner-Lambert Company Llc |
Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
|
|
CZ296967B6
(cs)
*
|
2002-02-01 |
2006-08-16 |
Zentiva, A.S. |
Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
|
|
CN100379723C
(zh)
|
2002-02-19 |
2008-04-09 |
特瓦制药工业有限公司 |
阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙
|
|
GB0218781D0
(en)
|
2002-08-13 |
2002-09-18 |
Astrazeneca Ab |
Chemical process
|
|
GB0312896D0
(en)
|
2003-06-05 |
2003-07-09 |
Astrazeneca Ab |
Chemical process
|
|
US7790197B2
(en)
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
US7655692B2
(en)
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
|
AU2003247327A1
(en)
*
|
2003-07-15 |
2005-01-28 |
Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. |
Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
|
|
UY28501A1
(es)
|
2003-09-10 |
2005-04-29 |
Astrazeneca Uk Ltd |
Compuestos químicos
|
|
GB0324791D0
(en)
|
2003-10-24 |
2003-11-26 |
Astrazeneca Ab |
Chemical process
|
|
CZ298382B6
(cs)
*
|
2004-03-10 |
2007-09-12 |
Zentiva, A. S. |
Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
|
|
ATE545629T1
(de)
*
|
2004-03-17 |
2012-03-15 |
Ranbaxy Lab Ltd |
Verfahren zur herstellung von atorvastatin- calcium in amorpher form
|
|
US7875731B2
(en)
|
2004-05-05 |
2011-01-25 |
Pfizer Inc. |
Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
|
|
CA2701710C
(en)
|
2004-07-20 |
2013-08-27 |
Warner-Lambert Company Llc |
Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
|
|
US7645888B2
(en)
*
|
2004-08-27 |
2010-01-12 |
Biocon Limited |
Process for the production of amorphous atorvastatin calcium
|
|
KR20070106680A
(ko)
*
|
2004-09-30 |
2007-11-05 |
닥터 레디스 레보러터리즈 리미티드 |
비정질 아토르바스타틴 칼슘
|
|
AU2005298383A1
(en)
|
2004-10-28 |
2006-05-04 |
Warner-Lambert Company Llc |
Process for forming amorphous atorvastatin
|
|
WO2006048888A1
(en)
*
|
2004-11-01 |
2006-05-11 |
Jubilant Organosys Limited |
Novel process for the preparation of amorphous atorvastatin calcium salt
|
|
ES2263370B1
(es)
*
|
2005-02-16 |
2007-12-01 |
Ercros Industrial, S.A. |
Atorvastatina calcica amorfa estabilizada y procedimiento para su obtencion.
|
|
WO2007052296A2
(en)
*
|
2005-08-23 |
2007-05-10 |
Kopran Research Laboratories Ltd |
A process of preparing amorphous atorvastatin calcium
|
|
ES2270722B1
(es)
*
|
2005-09-15 |
2008-03-01 |
Ercros Industrial, S.A. |
Procedimiento para la obtencion de atorvastatina calcica amorfa.
|
|
CA2547216A1
(en)
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
|
ATE466840T1
(de)
|
2005-11-21 |
2010-05-15 |
Warner Lambert Co |
Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
|
|
WO2007061849A2
(en)
*
|
2005-11-23 |
2007-05-31 |
Merck & Co., Inc. |
Method of generating amorphous solid for water-insoluble pharmaceuticals
|
|
EP2185527A2
(en)
*
|
2007-07-11 |
2010-05-19 |
Actavis Group PTC EHF |
Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
|
|
WO2009082362A1
(en)
*
|
2007-11-05 |
2009-07-02 |
Ulkar Kimya San. Ve Tic. A.S. |
A method for producing statins in pure form
|
|
EP2075246A1
(en)
|
2007-12-27 |
2009-07-01 |
M. J. Institute of Research |
A process for preparation of amorphous form of atorvastatin hemi-calcium salt
|
|
WO2009090544A2
(en)
*
|
2008-01-16 |
2009-07-23 |
Matrix Laboratories Limited |
Process for producing amorphous atorvastatin calcium
|
|
WO2009139730A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Ulkar Kimya San. Ve Tic. A.S. |
Preparation of novel non-crystalline forms of atorvastatin calcium
|
|
CN113321607A
(zh)
*
|
2020-02-28 |
2021-08-31 |
北京福元医药股份有限公司沧州分公司 |
一种阿托伐他汀钙中间体的纯化方法
|
|
CN114213270B
(zh)
*
|
2021-12-17 |
2024-05-28 |
江苏阿尔法药业股份有限公司 |
一种利用连续流微通道反应器合成阿托伐他汀钙中间体的方法
|